You are currently viewing archive.bio.org. Head to our home page to check out our fresh new look!

BIO Investor Forum Business Roundtable

Financing: Dreaming of Public Exits-If not Now, then When...and How? 

Tuesday, October 25th, 9:30am - 10:25am

The latest IPO window has stalled and global macro events threaten to completely shut it. Meanwhile, reverse mergers in Biotech continue to gain momentum with eight transactions in the last year alone. As chilly winds continue to blow through the latest IPO window, more private companies are considering this option among others. This panel will examine the current financing environment and common hurdles private executive teams need to be aware of as they pursue the public path. 

Moderator:

  • David Parrot, Managing Director, BMO Capital Markets

Panelist:

  • Alan H. Auerbach, President & Chief Executive Officer, Puma Biotechnology, Inc.
  • Marc Beer, President & CEO, Aegerion Pharmaceuticals, Inc.
  • Paul J. Hastings, President & Chief Executive Officer, OncoMed Pharmaceuticals, Inc.
  • Jonathan MacQuitty, PhD, Partner, Abingworth

Who's Who

 

Alan H. Auerbach - Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc., a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009.

Mr. Auerbach founded Cougar Biotechnology in May 2003 and served as the company's Chief Executive Officer, President and a Member of its Board of Directors until July 2009 when Cougar was acquired by Johnson & Johnson. From July 2009 until January 2010, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate, for the treatment of advanced prostate cancer.

Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was a Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by the company. During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented clinical trials in the field of oncology.

Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California.

Paul J. Hastings - Mr. Hastings brings more than 20 years of experience as a biotechnology and pharmaceutical industry executive. He has served as President and CEO of OncoMed Pharmaceuticals since January 2006. Prior to joining OncoMed, Mr. Hastings was President and Chief Executive Officer of QLT, Inc. Previous to that, Mr. Hastings served as President and Chief Executive Officer of Axys Pharmaceuticals, which was acquired by Celera Corporation in 2001. From 1999 to 2001, Mr. Hastings served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation. Prior to that, he was President and Chief Executive Officer of LXR Biotechnology. Mr. Hastings also held a series of management positions of increasing responsibility at Genzyme Corporation, including serving as President of Genzyme Therapeutics Europe as well as President of Worldwide Therapeutics. Mr. Hastings also served as Vice President, Marketing and Sales and General Manager, Europe for Synergen, Inc., and previously held a series of marketing and sales management positions with Hoffmann-La Roche. Mr Hastings was recently Chairman of the Board of Proteolix (sold to Onyx Pharmaceuticals in 2009), and served on the boards of ViaCell (sold to Perkin-Elmer in 2008), and Cerimon Pharmaceuticals. He is currently Chairman of the Board of the Bay Area Biosciences Association (Bay Bio) and serves on the executive committee of the board of directors of the Biotechnology Industry Association. He received a Bachelor of Science degree in pharmacy from the University of Rhode Island.

Jonathan MacQuitty, PhD - Jonathan has more than 15 years of operational experience in life science companies and 12 years of venture capital experience. His directorships have included Adiana, Dicerna, Entelos, Guava, Gynesonics, Iconix, Labcyte, ParAllele BioScience, Personalis, SFJ Pharma and Sunesis Pharmaceuticals. He joined Abingworth in 1999 as President and Director of the company’s US subsidiary, Abingworth Management Inc, and is based at the firm’s offices in Menlo Park, California. Before joining Abingworth he was an adviser to a Japanese venture capital firm. Between 1988 and 1997 he was CEO of GenPharm International, a biotech company in which Abingworth invested. Before this he held business development positions at Genencor and Genentech. He has served on the Board of the Biotechnology Industry Organisation (BIO). Jonathan has an MA in Chemistry from Oxford University, a PhD in Chemistry from the University of Sussex and an MBA from Stanford University. Jonathan is responsible for Abingworth’s Menlo Park office and focuses on West Coast deals.

David Parrot - David joined BMO Capital Markets in July 2010 as a Managing Director in the Healthcare Group. He has more than 20 years of investment banking experience and is responsible for covering the biopharmaceutical sector. Prior to joining BMO Capital Markets, David spent more than 12 years with Piper Jaffray as a Managing Director covering the biopharmaceutical sector. More recently, David was the Head of Healthcare Investment Banking at Montgomery & Co. and a member of its Executive Committee. David began his banking career at Manufacturers Hanover as well as SBC Warburg Dillon Reed.

David received an MBA from the Haas School of Business at the University of California, Berkeley and a Bachelor of Arts from Middlebury College.
Conferences and Events: 
BIO Investor Forum

BIO Investor Forum Advisory Committee

The 11th Annual BIO Investor Forum Advisory Committee will be annouced Spring 2012.  Please see below for last year's committee.

 

10th Annual BIO Investor Forum Advisory Committee

John Chambers Managing Director &
Head of Healthcare Investment Banking		 Roth Capital Partners
Annette Grimaldi Managing Director BMO Capital Markets
James, I. Healy, MD, PhD General Partner Sofinnova Ventures, LLC
Adam Koppel, MD, PhD Managing Director Brookside Capital, LLC
Ronald W. Lennox, DPhil Founder CHL Medical Partners, LLC
Gail Maderis President & CEO  BayBio
Gwen A. Melincoff SVP, Business Development,
Strategic Investment Group		 Shire Pharmaceuticals, Inc.
Jeffrey M. Ostrove, PhD President & Chief Executive Officer Ceregene Inc.
Andrew J. Schwab Founder & Managing Partner 5AM Ventures, LLC
Katya Smirnyagina, PhD Venture Partner Alta Partners, LLC
Samuel Wu, MD, PhD  Managing Director Medimmune Ventures
Asish K. Xavier, PhD Vice President Johnson & Johnson
Development Corporation
Conferences and Events: 
BIO Investor Forum

Enhancing America’s Competitive Edge

Submitted by admin on Wed, 2011-10-26 15:03

Discovery to Step Out of the Shadows at BIO Investor Forum

Submitted by admin on Mon, 2011-10-17 11:42

BIO Announces Plenary Sessions for 10th Annual BIO Investor Forum

Submitted by tcooley on Thu, 2011-10-06 15:51

BIO Announces Presenting Companies for 10th Annual BIO Investor Forum

Submitted by ahirsch on Tue, 2011-09-06 13:39

BIO Investor Forum Presenter Resource Center

Deadlines  |  Registration Instructions  |  Presenter Toolkit  |  Media Toolkit

The 14th Annual BIO Investor Forum assembles a select group of early and established private companies, as well as emerging public companies, to give company presentations throughout the event. The presentations feature over 110 biotech companies poised to join the growth and IPO “watch list” in 2015, as well as a number of nonprofit and venture philanthropy organizations.

If you're a presenting company, please refer to this page for all upcoming deadlines, important information, and logistical details for the 14th annual event.

Upcoming Deadlines

  • Registration opens July, 2015
  • Early-Bird Registration Deadline: August 27, 2015
  • One-on-One Partnering Opens: August 2015
  • Hotel Discount Deadline: October 5, 2015

Registration Instructions

All presenters must be issued codes in order to begin registration. Those who have confirmed their presentation should email their package selection and number of attendees to present@bio.org. Further instruction will then be provided. Presenter registration options are:

Option A) Individual Presentation Package:
This option allows you to register your presenter and pay your presentation fee. All companies in the regular private and public presentation track should select this option. Presentation code is required.

Option B) Discovery Track Company:
Corporations qualifying for the Discovery Track rates include only the following: Discovery Track corporations are "pre-emerging" biotech companies, qualifying as seed and A-round companies incorporated after 2010 that have raised, or are looking to raise, less than $25M total through October 2015. For this event, Discovery Track companies must use biotechnology or related technologies for research and development of drug products or diagnostics. For those companies that want the Discovery Track rate for a company presentation, they also must be first-time presenters at the BIO Investor Forum. This option allows you to register each person and pay your presentation fee separately.

Presenter Toolkit

Below please find resources and information to help guide you through your presentation.

  • Presenter Checklist: Important deadlines regarding your presentation and Partnering. Checklists will be sent to all presenters upon confirmation of a presentation spot.
  • Presentation Details & Guidelines: Read all the logistics to ensure your presentation goes smoothly.
  • Investor Kits: All investor kits/company literature will need to be sent to BIO's offices, and not the Parc 55. Please email present@bio.org to notify us that you will be sending materials. You will then receive a shipping deadline and form. We cannot guarantee display if any materials are sent directly to the hotel.
  • Webcasting: Those interested will have the option of webcasting their presentation for an additional fee. Presenters can order webcasting here.
  • BIO Investor Forum Presentation Title Slide: Please feel free to download this PowerPoint and use it for your presentation, although it is not required. 

Media Toolkit

 

Selection Process

The 14th Annual BIO Investor Forum features a mix of later-stage and emerging private companies, early-stage public companies, and patient advocacy groups from around the globe. Companies selected to present generally focus on biotechnology therapeutics, as opposed to those exclusively developing medical devices or platform technologies. Corporations qualifying for the Discovery Track rates include only the following: Discovery Track corporations are "pre-emerging" biotech companies, qualifying as seed and A-round companies incorporated after 2010 that have raised, or are looking to raise, less than $25M total through October 2015. For this event, Discovery Track companies must use biotechnology or related technologies for research and development of drug products or diagnostics. For those companies that want the Discovery Track rate for a company presentation, they also must be first-time presenters at the BIO Investor Forum. This option allows you to register each person and pay your presentation fee separately.

If you are a company who has not been selected to present but would like to apply, please follow this link and send in your application.

Conferences and Events: 
BIO Investor Forum

BIO Investor Forum Checklist for Presenting Companies

Companies selected to present will be notified via mail. Once your presentation is confirmed with us, you will receive the information listed below. All items must be completed. If you have not received an invitation, but would like to present, please fill out a short application online.

 

 

 

Checklist Item Deadline

1. Choose your Registration Package.
 		  

2. Email present@bio.org with your selection in order to receive your Registration Package Code.
 
Early Bird
Registration Deadline:
August 27, 2015
Option A) Presenter Group Package:
Includes your presentation fee, registration for your presenter, plus two addtional employees within the presenting company. Choose this if you're bringing three or more individuals to the event.

Option B) Individual Presentation Package:
This option allows you to register your presenter and pay your presentation fee. You should also choose this option if you need to register your presenter, and pay for an additional attendee.

Option C) Discovery Track Company:
Corporations qualifying for the Discovery Track rates include only the following: Discovery Track corporations are "pre-emerging" biotech companies, qualifying as seed and A-round companies incorporated after 2009 that have raised, or are looking to raise, less than $25M total through October 2015. For this event, Discovery Track companies must use biotechnology or related technologies for research and development of drug products or diagnostics. For those companies that want the Discovery Track rate for a company presentation, they also must be first-time presenters at the BIO Investor Forum. This option allows you to register each person and pay your presentation fee separately.

3. Create and publish your company profile within the BIO One-on-One Partnering System


The Partnering System will open in early August. Registered attendees will automatically be sent their login information, otherwise, after the launch you will receive login details within 2 business days from the date of your registration.
 		 One-on-One Partnering to Open:
Early August

Publish Your Profile:
Upon Login
4. Please provide the contact information for the following individuals:

Presenter:
Name:
Title:
Email:
Onsite Phone Number:

Media Contact:
Name:
Title:
Company:
Email:
Phone:
 Media List Available:
Late September

5.  Order Webcasting

Webcasting will be available to all interested parties at this year's event for an additional fee. More information will be provided shortly.
 		 Early-Bird
Registration Deadline:
TBD
 
6. Book Your Stay at the Parc 55 San Francisco.

BIO has secured discounted rates at The Parc 55, the BIO Investor Forum conference venue, for attendees of the event. More information, including the link to register and discount instructions, can be found here.		 Discount Rate Expires:
October 5, 2015

7. Review the Presentation Details & Guidelines
 
Prior to conference

8. Send your Investor Kits/Company Literature to The Parc 55 Hotel. 


BIO displays marketing materials for presenting companies at the Parc 55 Hotel, allowing attendees to view and keep information about these companies. However, if these materials are shipped without notice, we cannot guarantee their display.

a. Please notify present@bio.org if you intend on sending any materials. A shipping form and further instruction will then be provided.
 		 To Arrive:
TBD

9. Submit your presentation to the Speaker Ready Room onsite.


All presentations must be uploaded onsite via USB or flash drive, and cannot be sent electronically to BIO staff. Please also note that submitting your presentation for webcasting purposes is not a substitute for uploading your presentation in the Speaker Ready Room.

More information, included Speaker Ready Room hours and location, will be provided shortly.
 
Minimum:
3 hours prior to your
Presentation Time

 

Conferences and Events: 
BIO Investor Forum